Scanfil Oyj · OMXHEX:SCANFL
Scanfil Oyj — Investor Day (September 2026)
41 slides from Scanfil Oyj's investor day presentation, Sep 29, 2026
Slide 1: Scanfil Group
Scanfil Group
Slide 2: Business Strategy
Business Strategy Section 1: Progress Since Capital Markets Day 2024
Slide 3: Growth Accelerated and Gain Momentum
Growth Accelerated and Gain Momentum Turnover Comparable EBITA +28.1% +34.2% 280 20 7.6 259.0 260 7.4 7.4 7.4 7.3 7.3 7.3 240 229.1 7.2 7.2 220 212.3 211.0 15 7.0 202.2 7.0 200 195.5 192.6 191.3 6.8 6.8 180 173.3 6.6 10 6.5 160 6.4 140 6.2 120 14.3 12.8 15.5 12.6 14.2 14.1 15.5 15.6 18.6 5 6.0 100 Q
Slide 4: Performance H1 2026
Growth and Profitability Ahead of Last Year Performance H1 2026 TURNOVER ORGANIC GROWTH COMPARABLE EBITA COMPARABLE EBITA MARGIN EUR 488.0m 5.6% EUR 34.2m 7.0% +23.6% total growth Positive Organic Growth +27.7% vs last year +0.2 pp vs last year H1 2025: EUR 394.8m Continued H1 2025: EUR 26.8m H1 202
Slide 5: Our Mission and Global Footprint
Our Mission and Global Footprint Mission: Scanfil helps customers to succeed by providing effective and innovative solutions that bring products from idea to life and maintain product competitiveness over the lifespan. Northern Europe 1,200 people 4,700+ Employees worldwide Americas ~500 people Cent
Slide 6: New Customer Deals Are Driving Organic Growth
New Customer Deals Are Driving Organic Growth +72.7% 80 72.3 72 70 61 59.2 60 51.7 50 46.6 44.3 40.2 41.7 41.7 40 30 20 10 0 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 6
Slide 7: Published New Customer Wins
Published New Customer Wins 6 PUBLIC CUSTOMER WINS SINCE 2024 · 4 SEGMENTS · 3 CONTINENTS 16 DEC 2025 18 JUN 2025 26 JUN 2025 VALMET EMERSON LIQUID INSTRUMENTS Industrial Industrial Medtech & Life Science Partnership deepened into new locations and New customer: control units for Rosemount Tank Moku
Slide 8: Positive Development in Customer Satisfaction
Positive Development in Customer Satisfaction 10 60 9 8.54 8.4 8.43 8.6 50 8.28 8.33 8.16 8 7.97 7.98 8 7.92 7.84 7.35 7.49 7 6.98 40 6 30 54 5 50 45 45 38 20 4 37 37 3 22 25 22 22 10 16 2 5 7 0 1 -2 0 -10 Q2 19 Q4 19 Q2 20 Q4 20 Q2 21 Q4 21 Q2 22 Q4 22 Q2 23 Q4 23 Q2 24 Q4 24 Q2 25 Q4 25 Q2 26 Reco
Slide 9: Customer Group Development
Customer Group Development +188.2% +25.9% +21.9% +15.8% Aerospace & Defense Energy & Cleantech Industrial Medtech & Life Science • Driven by acquisitions and • Solid performance • Growth is driven mainly by • Long customer acquisition and brisk demand from existing • Strategic priority acquisitions
Slide 10: Investing in Additional Capacity
Investing in Additional Capacity 6 CAPACITY INVESTMENTS SINCE 2023 ACROSS 4 SITES · +21,700 m² · EUR 13.3m DISCLOSED · 4 COUNTRIES SEP 2023 · MAY 2025 JAN 2025 · SEP 2025 ATLANTA, USA JOHOR BAHRU, MALAYSIA New SMT line in 2023 after 50% area expansion; second manufacturing line added 2025 EUR 4.3m i
Slide 11: All Regions Increase Performance
All Regions Increase Performance Americas +68.0% APAC +5.4% 21 12 65 12 19 10.5 19.8 60 62.7 10 61.1 10 9.6 59.5 17 9.3 8.5 17.7 55 8.4 8.6 8.7 8.5 8.1 8.3 8 7.9 8 55.0 15 7.3 53.8 7.4 7.2 50 52.2 6.9 51.9 13 13.9 6.2 6 6.0 6 45 12.7 45.5 11 11.8 4.6 11.7 4 4 10.8 40 42.7 9 9.7 8.8 2 35 2 7 5 0 30 0
Slide 12: Customer Portfolio Richer and More Diversified
Customer Portfolio Richer and More Diversified 10 % 100% 19 % 45% 45% 46% 41% 47% 75% 31 % 50% 36% 42% 42% 46% 42% 25% 40 % 19% 13% 13% 13% 11% % of turnover in H1 2026 0% 2022 2023 2024 2025 H1 2026 Aerospace & Defense Energy & Cleantech The biggest customer TOP10 (ex. biggest) Rest Industrial Medt
Slide 13: Market and Our Strategy
Market and Our Strategy Section 2: Where do we play moving forward?
Slide 14: Market Fundamentals
EMS demand grows steadily towards 2030, led by outsourcing and industrial electronics Market Fundamentals USD 649bn USD 853bn 5.6% Global EMS market size, 2025 Forecast market size, 2030 EMS market CAGR, 2025-2030 Market drivers Outsourcing Supply chain resilience AI and electrification Defence and
Slide 15: Market's Organic Growth Drivers
Three of our four customer groups outgrow the EMS market Market’s Organic Growth Drivers Around 60% of Scanfil's turnover sits in segments growing faster than the EMS market average of 5.6% Market CAGR 2025-2030 Share of Scanfil Medtech & Life Science 8.9% 19% Energy & Cleantech 8.5% 31% Aerospace &
Slide 16: Global Industry Consolidation
M&A has stayed elevated worldwide, with European and Nordic players among the most active buyers Global Industry Consolidation 304 deals 21 deals USD 2.55bn Electronics parts and equipment Sanmina's purchase of AMD's ZT North American EMS transactions in transactions globally in 2024, after 313 Syst
Slide 17: Market Segmentation
Market Segmentation High mix / low-to-mid volume High mix / high volume Scanfil's core: industrial customers, box build, PCBAs Fragmented demand, harder to serve profitably at and system integration scale MIX high → low Low mix / low volume Low mix / high volume Consumer mass production - price-driv
Slide 18: Where We Want to Play
We aim at the space where market leadership, global reach and our chosen segments overlap Where We Want to Play Leaders in their field Companies that set the standard in their own market and expect Leaders in their Global by nature a partner able to keep that standard. field Global by nature Product
Slide 19: A Race to Critical Mass
Global customers want to work with equals, and the size needed to qualify keeps rising A Race to Critical Mass Our customers want to play with equals And the bar keeps rising As the industry consolidates, the scale required to stay on a global shortlist moves up every year. Growth is not only ambiti
Slide 20: How We Allocate Capital to Sustain Growth
Four commitments that fund and pace our long-term growth How We Allocate Capital to Sustain Growth ~2.5% Our capex ambition: about 2.5% of revenue invested every year in the current operations capex ambition, % of revenue - capacity, capability and automation - so the existing business can carry fut
Slide 21: M&A Complementing Our Growth Journey
M&A Complementing Our Growth Journey Acquisition Criteria • Similar production capabilities as Scanfil Target business • Attractive customer base Geography Operates in Scanfil’s regions • Revenues of 50-150 MEUR Financials • EBITDA margin >7% • Track-record of growth and profitability Deal structure
Slide 22: Building the Resources Behind Our Growth
Short-term moves to strengthen leadership, competence and talent Building the Resources Behind Our Growth Business leadership Strengthen business leadership competence in each region, owning management of the strong competence in every region operations, the customer interface and the M&A interface
Slide 23: Employee Engagement Results Moving in the Right Direction
F R O M 2 0 2 4 P R O G R E S S T O 2 0 2 6 A C T I O N Employee Engagement Results Moving in the Right irection All measured engagement drivers remained stable or improved — Co-operation 83 and Immediate Manager 82 remain our strongest foundations. DEVELOPMENT 2024 → 2025 ACTIONS IN 2026 EES 2026 T
Slide 24: Expected Outcome
Expected Outcome Section 3: What success should look like when everything comes together?
Slide 25: The Size We Need by 2030: EUR 1.8bn+
Scale is the condition for staying relevant to global customers The Size We Need by 2030 EUR 1.8bn+ To be a sustainable player on the global market, we need turnover of EUR 1.8 billion by 2030.
Slide 26: Long-Term Financial Targets – Adjusted Growth Target
Long - Term Financial Targets – Adjusted Growth Target TURNOVER PROFITABILITY DEBT DIVIDEND Dividend Growth 15%* EBITA 7-8%* Net Debt/EBITDA 1-2 1/3 of EPS** * Target over a business cycle to be considered as long term average includes organic and continuous flow of M&A ** Target are established ove
Slide 27: Strategy for 2026–2030: Geared for Growth
Strategy for 2026–2030: Geared for Growth CU S T OME RS | We h elp th em sh ap e th eir ind ustr ies, g lo b ally Global thinking · Local execution — responsibility close to our customers and factories GROWTH EFFICIENCY Customer Groups Medtech & Life Geographic Offering Acquisitions Dream Factory Sc
Slide 28: Why to Invest in Scanfil?
Why to Invest in Scanfil? • Strong customer portfolio and organic growth • Sector leading customers • G ood market position in the growth segments: Aerospace & Defense, Energy & Cleantech an d Medtech & Life Science • Continuous investments in growth and good growth prospects • Stable profitabilit y
Slide 29: Contact information and analysts
Contact information and analysts Carnegie AB, Stockholm Marcus Develius +46 70 848 85 67 [email protected] Inderes Oyj CHRISTOPHE SUT, CEO Antti Viljakainen +358 407 318 411 +358 44 591 2216 [email protected] [email protected] Nordea Oyj IIRIS HEISKANEN, CFO Pasi Väisän
Slide 30: Disclaimer
Disclaimer Not to be published or distributed, directly or indirectly, in any country where its distribution or publication is unlawful. Forward looking statements: certain statements in this presentation may constitute "forward - looking" statements which involve known and unknown risks, uncertaint
Slide 31: Updated Financial Targets
Updated Financial Targets Iiris Heiskanen CFO
Slide 32: Early Observations as Scanfil's New CFO
Early Observations as Scanfil’s New CFO A broader growth Consistent C ash and financial platform execution flexibility 29 - Sep - 26 2
Slide 33: Updated Financial Targets
Updated Financial Targets Target Previous Updated Turnover growth 10% p.a. 15% p.a. Comparable EBITA 7– 8% 7– 8% Net debt / EBITDA < 1.5x 1– 2x Dividend ~1/3 of EPS ~1/3 of EPS Targets are established over the business cycle and should be consider as long - term averages. 29 - Sep - 26 3
Slide 34: The Growth Strategy is Delivering a Step in Scale
The G rowth Strategy is Delivering a Step in Scale • Growth target 15% p.a., combination of organic and inorganic growth • 2016 - 2024 mainly organic g rowth , where 2021– 2023 was reflected by component shortages and low- margin pass - through sales • Three acquisitions in past three years: SRX (20
Slide 35: Solid Profitability - Now with a Larger Scale
Solid P rofitability - Now with a Larger Scale • MANAGEMENT FOCUS Comparable EBITA has returned to the 7 – 8% range s ince 2023 and the target is unchanged • G rowth remains the priority while keeping the margin at the target level • S cale, utilisation and customer mix support gradual improvement •
Slide 36: Strong Cash flow - Swings from Working Capital
Strong Cash flow - Swings from Working Capital • Cash generation is structurally positive • Negative 2021 – 2022 reflects inventory build during component shortages • Lower LTM 6/2026 reflects working capital tied up by growth • Capex has been stable at ~ 2- 2.5% of turnover Note: Free cash flow = o
Slide 37: Capital is Tied Up in Growth - Available from Inventories
Capital is Tied Up in Growth - Available from Inventories • Inventory built in 2021 - 2023 to protect deliveries, then released • NWC improved to 22.5% of turnover by 2025 . Growth and acquisitions lifted NWC in H1 2026 • Inventory is focus area to drive NWC efficiency • Expected to return towards t
Slide 38: Strong Balance Sheet with Growth Capacity
Strong Balance Sheet with Growth Capacity • Net debt / EBITDA target 1 - 2x • Leverage at 1.6 0 x in H1 2026 leaves MANAGEMENT FOCUS funding capacity for growth • Available liquidity in H1 2026 EUR 195.8 million in cash and undr aw n credit facilities 29 - Sep - 26 8
Slide 39: Growing EPS and Dividend
Growing EPS and Dividend • EPS up from EUR 0.40 in 2017 to EUR 0.63 in 2025 • Dividend growing since 2012 • Dividend p ayout at 30 – 40% of EPS CONFIDENTIAL 29 - Sep - 26 9
Slide 40: Summary
Summary A broader growth platform Growth comes from organic expansion and acquisitions that add markets and capabilities Consistent execution Margin inside 7 – 8% on a larger base, target unchanged Cash and financial flexibility Cash generation is structurally positive with working capital driving t
Slide 41: 29 - Sep - 26 CONFIDENTIAL
11 29 - Sep - 26 CONFIDENTIAL